Progress in Research and Application of Novel Tumor ICIs

ICIs have become a significant therapy in the course of tumors treating, which is particularly effective in relieving T-cell inhibition, activating the ATIR of the immune system. The ICIs represented by PD1 have been widely used in clinics. In this paper, the principle, biological characteristics and clinical application of ICIs in the treatment of cancer are comprehensively discussed. By preventing ICs from attaching to their ligand, which eliminate the immune function inhibition brought on by ICs, thus reactivating immune cells to play anti-tumor role. Currently, a number of ICIs have achieved remarkable results in clinical applications for anti-tumor. For example, inhibitors targeting CTLA-4, PD-1 and PD-L1 have been effectively employed in the therapeutic management of a number of malignant tumors, including non-small cell lung cancer and melanoma. However, the current application of ICIs against tumors is not mature enough. This paper focuses on the existing drawbacks of ICIs (such as their drug toxicity and drug resistance) as well as the in-depth exploration of the application prospects of ICIs. For example, in order to improve the responsiveness to immunotherapy, the clinical use of special antibodies can simultaneously target two different antigens. By acting on two synergistic or complementary signaling pathways, it can effectively enhance the anti-tumor immunity of ICIs and reduce the drug resistance of ICIs. It also provides ideas for the further improvement of ICI therapy.